APONTIS PHARMA Reports Strong Financial Growth Amid Planned Merger

APONTIS PHARMA AG, a German pharmaceutical leader in Single Pill combinations, marked a notable 31.1% sales increase to EUR 48.5 million in 2024. The company also realized an EBITDA improvement of EUR 16.8 million, reaching EUR 3.5 million. These figures reflect strategic restructuring and cost reductions started in 2023.

The firm plans a squeeze-out and merger with Zentiva AG. This move will continue the success of Single Pill combinations under new management. Notably, sales in the cooperation business rose 36%, hitting EUR 12.6 million, aided by a deal with Novartis. The overall Single Pill revenue soared by 34.3%, mainly driven by Atorimib sales.

Additionally, APONTIS PHARMA improved profitability, closing the fiscal year with a EUR 0.8 million net profit. The equity ratio increased to 69.9%. Looking ahead, further growth is anticipated in 2025, with plans for European market expansion under Zentiva's Control.